Delivering Co-stimulatory Tumor Necrosis Factor Receptor Agonism for Cancer Immunotherapy: Past, Current and Future Perspectives

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 May 14

PMID 37180119

Authors

Osman Dadas

Ayse Ertay

Mark S Cragg

Affiliations

Soon will be listed here.

Abstract

The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients.

Citing Articles

MD Simulation Reveals a Trimerization-Enhanced Interaction of CD137L with CD137.

Wang H, Wu J, Fang Y, Li Q Int J Mol Sci. 2025; 26(5).

PMID: 40076530 PMC: 11899465. DOI: 10.3390/ijms26051903.

First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.

Johnson M, Hong D, Brana I, Schoffski P, Galvao V, Rangwala F Invest New Drugs. 2025; .

PMID: 40042547 DOI: 10.1007/s10637-025-01518-7.

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N Front Immunol. 2025; 15:1473815.

PMID: 39867912 PMC: 11757143. DOI: 10.3389/fimmu.2024.1473815.

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.

Croft M, Salek-Ardakani S, Ware C Nat Rev Drug Discov. 2024; 23(12):939-961.

PMID: 39448880 DOI: 10.1038/s41573-024-01053-9.

Exploring miRNA therapies and gut microbiome-enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting.

Sandhanam K, Tamilanban T, Bhattacharjee B, Manasa K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39382681 DOI: 10.1007/s00210-024-03479-9.

References

Richman L, Vonderheide R . Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res. 2014; 2(1):19-26. PMC: 3883444. DOI: 10.1158/2326-6066.CIR-13-0152. View

Nikolopoulos G, Smith C, Brookes S, El-Asrag M, Brown C, Patel A . New missense variants in RELT causing hypomineralised amelogenesis imperfecta. Clin Genet. 2020; 97(5):688-695. PMC: 7216828. DOI: 10.1111/cge.13721. View

Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

Qamar N, Fuleihan R . The hyper IgM syndromes. Clin Rev Allergy Immunol. 2013; 46(2):120-30. DOI: 10.1007/s12016-013-8378-7. View

Durandy A, Revy P, Fischer A . Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Adv Immunol. 2004; 82:295-330. DOI: 10.1016/S0065-2776(04)82007-8. View

van Montfrans J, Hoepelman A, Otto S, van Gijn M, van de Corput L, de Weger R . CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol. 2011; 129(3):787-793.e6. PMC: 3294016. DOI: 10.1016/j.jaci.2011.11.013. View

Keller A, Schildknecht A, Xiao Y, van den Broek M, Borst J . Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity. 2008; 29(6):934-46. DOI: 10.1016/j.immuni.2008.10.009. View

Peperzak V, Veraar E, Keller A, Xiao Y, Borst J . The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation. J Immunol. 2010; 185(11):6670-8. DOI: 10.4049/jimmunol.1000159. View

Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J . CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. J Immunol. 2017; 199(12):4110-4123. PMC: 5713498. DOI: 10.4049/jimmunol.1700606. View

10.

Ma L, Chen S, Mao X, Lu Y, Zhang X, Lao X . The association between TNFR gene polymorphisms and the risk of Hepatitis B Virus-Related Liver Diseases in Chinese population. Sci Rep. 2018; 8(1):9240. PMC: 6006281. DOI: 10.1038/s41598-018-27623-7. View

11.

Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit G, Pfizenmaier K . Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009; 183(3):1851-61. DOI: 10.4049/jimmunol.0802597. View

12.

Muller N, Wyzgol A, Munkel S, Pfizenmaier K, Wajant H . Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 2008; 275(9):2296-304. DOI: 10.1111/j.1742-4658.2008.06382.x. View

13.

Heckel F, Turaj A, Fisher H, Chan H, Marshall M, Dadas O . Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun Biol. 2022; 5(1):229. PMC: 8921514. DOI: 10.1038/s42003-022-03182-6. View

14.

Tesselaar K, Arens R, van Schijndel G, Baars P, van der Valk M, Borst J . Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2002; 4(1):49-54. DOI: 10.1038/ni869. View

15.

Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, Lin J . Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009; 114(16):3431-8. PMC: 2765679. DOI: 10.1182/blood-2009-05-223958. View

16.

Sica G, Zhu G, Tamada K, Liu D, Ni J, Chen L . RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-kappaB. Blood. 2001; 97(9):2702-7. DOI: 10.1182/blood.v97.9.2702. View

17.

Hendriks J, Xiao Y, Rossen J, van der Sluijs K, Sugamura K, Ishii N . During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol. 2005; 175(3):1665-76. DOI: 10.4049/jimmunol.175.3.1665. View

18.

Snell L, McPherson A, Lin G, Sakaguchi S, Pandolfi P, Riccardi C . CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol. 2010; 185(12):7223-34. DOI: 10.4049/jimmunol.1001912. View

19.

van de Ven K, Borst J . Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015; 7(6):655-67. DOI: 10.2217/imt.15.32. View

20.

Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S . Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica. 2012; 98(3):473-8. PMC: 3659923. DOI: 10.3324/haematol.2012.068791. View